Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci 2016 Sep 08;17(9)
Date
09/13/2016Pubmed ID
27618026Pubmed Central ID
PMC5037783DOI
10.3390/ijms17091506Scopus ID
2-s2.0-84987722672 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizing the need for the development of new treatment regimens. Immunotherapy is a promising treatment modality to circumvent challenges in the management of MM. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with some already demonstrating a positive impact on patient survival. In this review, we will summarize the current standards of care and discuss major new approaches in immunotherapy for MM.
Author List
Al-Hujaily EM, Oldham RA, Hari P, Medin JAAuthors
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of WisconsinJeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AnimalsAntibodies, Monoclonal
Humans
Immunotherapy, Adoptive
Multiple Myeloma
